Major Depressive Disorder Market Forecast Highlights A $7.49 Billion Opportunity For Industry Participants

Major Depressive Disorder Market Report

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Major Depressive Disorder Market Revenue Outlook: What CAGR Lies Ahead Through 2030?

The market size for major depressive disorder has shown consistent expansion in recent years. It is projected to increase from $6.26 billion in 2025 to $6.44 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 2.9%. Factors contributing to its historical growth include the rising prevalence of depressive disorders, heightened societal awareness of mental health, broader access to antidepressant medications, the development of psychiatric care infrastructure, and improved diagnostic guidelines for mood disorders.

The major depressive disorder market is projected to experience consistent expansion over the upcoming years. It is anticipated to grow to $7.49 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 3.9%. This growth in the forecast period can be attributed to an escalating mental health burden due to lifestyle stress, the increasing adoption of digital mental health platforms, a growing demand for personalized depression treatments, the expansion of insurance coverage for mental health care, and continued innovation in neuromodulation therapies. Major trends during this period include a rising adoption of combination therapy approaches, an increasing demand for non-invasive brain stimulation treatments, enhanced awareness and diagnosis of depression, the expansion of telepsychiatry and remote mental health care, and rising acceptance of novel and rapid-acting antidepressants.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=86452102&type=smp&name=Major%20Depressive%20Disorder%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Major Depressive Disorder Market Growth Factors: What’s Supporting Expansion?

An increase in instances of substance and alcohol abuse is projected to boost the expansion of the major depressive disorder market. These terms refer to patterns of overindulgent and detrimental substance use, including alcohol, which can result in adverse physical, psychological, and social outcomes. This often accompanies major depressive disorder, with both conditions mutually exacerbating each other and substantially elevating the danger of physical and mental damage. For example, data from July 2024, based on a survey from the US-based Department of Health and Human Services’ Substance Abuse and Mental Health Services Administration, revealed that 3.1% of people (8.9 million) misused opioids in 2023. Concurrently, 21.8% of individuals aged 12 or older reported using marijuana, establishing it as the most widely used illicit drug. Furthermore, 9.4% of individuals aged 12 or older had vaped nicotine in the preceding month, marking an uptick from 8.3% in 2022. Consequently, the growing prevalence of substance and alcohol abuse is fueling the expansion of the major depressive disorder market.

Major Depressive Disorder Market Segment Analysis: What Are The Core Market Categories?

The major depressive disorder market covered in this report is segmented –

1) By Treatment: Psychotherapy, Medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Other Treatments

2) By Diagnosis: Psychiatric Evaluations, Diagnostic And Statistical Manual of Mental Disorders (DSM-5)

3) By End-User: Clinics, Hospitals, Other End-Users

Subsegments:

1) By Psychotherapy: Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT), Dialectical Behavior Therapy (DBT), Psychodynamic Therapy

2) By Medications: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants

3) By Electroconvulsive Therapy (ECT): Unilateral ECT, Bilateral ECT, Modified ECT

4) By Transcranial Magnetic Stimulation (TMS): Repetitive Transcranial Magnetic Stimulation (rTMS), Deep Transcranial Magnetic Stimulation (dTMS), Theta Burst Stimulation (TBS), Navigated Brain Stimulation (nTMS)

5) By Other Treatments: Cognitive Behavioral Therapy (CBT), Psychodynamic Therapy, Interpersonal Therapy (IPT), Vagus Nerve Stimulation (VNS), Ketamine Therapy, Bright Light Therapy, Psychedelic-Assisted Therapy, Medication (Antidepressants)

Major Depressive Disorder Market Industry Trends: What’s Reshaping Demand?

Companies operating within the major depressive disorder (MDD) market are concentrating on developing innovative solutions, such as prescription digital therapeutics (PDTs), to address the increasing need for scalable access to evidence-based psychotherapy, supplementary treatments for individuals with partial responses, and remote, data-driven care pathways. These PDTs are software-as-medical-device interventions dispensed by prescription, integrating clinically validated therapeutic content, remote engagement, adherence tools, and data capture for medical professionals. Unlike conventional antidepressant medications or in-person psychotherapy, PDTs offer repeatable, standardized, and remotely supervised behavioral interventions that can complement pharmacotherapy or bridge gaps where provider access is limited. For example, in April 2024, Otsuka Pharmaceutical Co., a pharmaceutical company based in Japan, in collaboration with Click Therapeutics, introduced Rejoyn (developed as CT-152). This prescription digital therapeutic received U.S. FDA authorization as an adjunctive treatment for adults with MDD who are already taking antidepressant medication. Rejoyn is a six-week, smartphone-delivered program centered on clinically validated cognitive-emotional brain-training exercises, specifically the Emotional Faces Memory Task/EFMT, and brief therapeutic lessons aimed at enhancing cognitive control over emotion. The application functions via prescribed delivery, allowing patients to download and complete scheduled sessions on their smartphones, while clinicians prescribe and oversee its usage. Its effectiveness was demonstrated in the MIRAI randomized, sham-controlled trial, which showed symptom improvement compared to the control group. Its distinct attributes include a neuromodulatory design targeting neural networks involved in emotion processing, remote and personalized reminders to improve patient adherence, and regulatory clearance as a medical device rather than a wellness application.

Major Depressive Disorder Market Top Companies Driving Competitive Growth

Major companies operating in the major depressive disorder market are Pfizer Inc., Janssen Research and Development LLC, Merck and Co. Inc., Novartis AG, Sanofi-Aventis US LLC, Bristol Myers Squibb Co., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Inc., Otsuka Pharmaceuticals Co. Ltd., Forest Laboratories Inc., H. Lundbeck A/S, Richter Gedeon plc, Allergan plc, Neurocrine Biosciences Inc., BlackThorn Therapeutics Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., Luye Pharma Group, BrainsWay Ltd., Neumora Therapeutics Inc., Chase Therapeutics Corporation, SAGE Therapeutics Inc., Relmada Therapeutics Inc., Fabre-Kramer Pharmaceuticals Inc., Vistagen Therapeutics Inc.

View The Full Major Depressive Disorder Market Report:

https://thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Major Depressive Disorder Market Regional Breakdown: Where Is Demand Concentrated?

North America was the largest region in the major depressive disorder market in 2025. The regions covered in the major depressive disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model